Item 1.01 Entry into a Material Definitive Agreement.

As previously disclosed in the Current Report on Form 8-K filed on December 7, 2020, Instadose Pharma, Corp., f/k/a Mikrocoze, Inc. (the "Company") entered into a non-binding letter of intent with Instadose Pharma, Corp., a corporation organized under the laws of Canada ("Instadose"), dated December 7, 2020 (as amended by the Amendment (as defined below), the "LOI"). On April 29, 2021, the Company entered into an amendment to the LOI ("Amendment"). The Amendment amends the exclusivity period prescribed in the LOI, extending such period until the earlier to occur of (i) either Party terminating the LOI and the proposed transaction providing notice to the other party, (ii) the consummation of the contemplated transaction, and (iii) July 31, 2021.

The foregoing description of the Amendment does not purport to be complete and is qualified in its entirety by reference to the complete text of the Amendment, a copy of which is filed with this Current Report on Form 8-K as Exhibit 10.1 and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.





(d) Exhibits.



Exhibit No.   Description

  10.1          Amendment to Letter of Intent, dated April 29, 2021, by and between
              Instadose Pharma Corp. and Instadose Pharma Corp. f/k/a Mikrocoze,
              Inc.





2

© Edgar Online, source Glimpses